Have to agree that there must be something we don't know about going on. Can't believe we could get this kind of volume off Stoll's confidence that the FDA will raise CX717 dosing limits. And a big move up due to the Organon buyout seems pretty far fetched too.
I promised myself that I would sell my $1.10 shares as soon as the stock hit $2.50. Of course now I can't even imagine selling. Iceberg is right - selling is harder than buying.